EOD v3.1 revision

• General: the tables controlling when Derived EOD 2018 Stage Group [818] utilizes the AJCC ID value. These tables had not been updated to reference the new AJCC IDs for the V9 schemas. This has been corrected. If you calculate the Derived EOD 2018 fields, It is recommended to run the derivations across all January 1, 2018 and later cases to ensure the correct Derived EOD 2018 Stage Group is captured. #108

Fix property name

Renamed rational to rationale #107

Pediatric 1.1 conversion fix

General Changes

• Conversion to Pediatric Regional Nodes: for Pediatric Schemas 9b, 9d, 9e: some rows had a Pediatric Regional Nodes value of 100-800. This was corrected to be 800.

See #106

New StagingTable fields

3 new fields were added to the StagingTable:

• Rational
• Additional Information
• Coding Guidelines

Note that this only adds support for these fields. There is no algorithm-specific data yet. See #105.

Pediatric conversion tables

In the prior release of the Pediatric 1.1 algorithm there were conversion tables that should have been included. By default the library strips out tables that are not used in any schema. We now also include and table with an identifier that starts with conversion_. See #104 for details.

Pedatric 1.1

Pediatric v1.1 changes:

• General Changes

  • Toronto T [9628], Toronto N [9629], Toronto M [9630], Toronto Stage Group [9631] were added to all schema. If the field is not defined for the schema, the default of N/A is set. X is used for Unknown.

• Acute Lymphoblastic Leukemia

  • Pediatric Primary Tumor [9623]: Minor revisions to wording in Notes 1, 2 and 3 for clarity
  • White Blood Cell Count [9621]: Note 3 related to the units of measurement was revised; Units of measure in the codes were revised to match

• Astrocytoma

  • Pediatric Primary Tumor [9623]: Note 2 related to the coding of /0 and /1 was added; sub-bullet for Note 3 was revised for clarity
  • Pediatric Mets [9625]: Note 2 related to Leptomeningeal metastases was added; Code 70 was revised to include more specified sites
  • BRAF Mutational Analysis [3940]: Note 3 sub-bullet was changed to "KIAA1549: BRAF gene fusion"; Code 3 was changed to match

• Ependymoma

  • Pediatric Primary Tumor [9623]: Existing Notes were revised for clarity; Note 2 was added describing how to code /0 and /1; Note 3 was added describing midline shift vs midline; Codes 150, 250 and 999 were revised for greater specificity

• Pediatric Mets [9625]: Note 1 was removed; Note 3 was moved to Note 1; a new Note 3 was added related to adjacent sites; Note 4 was added related to Leptomeningeal metastases; Codes 25, 35, and 45 were revised to add more specific sites

• Hepatoblastoma

  • Pediatric Mets [9625]: Code 10 was reworded to replace 'Lesser omentum' with 'Omentum (lesser and NOS) (see code 20 for greater omentum)'; Code 20 had 'Greater omentum (see code 10 for lesser omentum and omentum, NOS)' added
  • Pretext Clinical Staging [9626]: Note 3 sub-bullets were changed to include 'Caudate liver: Segment I'
  • Derived Pediatric Stage Group [9606]: calculation was revised to include Pretext Clinical Staging

• Hodgkin Lymphoma

  • Pediatric Primary Tumor [9623]: Note 7 related to Splenic involvement was added;
  • Derived Pediatric N [9605], Derived Pediatric M[9604]: XML ID was corrected, a space was accidentally included in the tag

• Medulloblastoma (5 schemas)

  • Pediatric Primary Tumor [9623]: Existing Notes were revised for clarity; Note 2 was added describing how to code /0 and /1; Note 3 was added describing midline shift vs midline; Codes 150, 250 and 999 were revised for greater specificity
  • Pediatric Mets [9625]: Note 1 was removed; Note 3 was moved to Note 1; a new Note 3 was added related to adjacent sites; Note 4 was added related to Leptomeningeal metastases; Codes 25, 35, and 45 were revised to add more specific sites

• Neuroblastoma

  • Schema Definition: for C700-C729, C751-C753, /0 and /1 were removed from Neuroblastoma
  • Pediatric Primary Tumor [9623]: Note 1 was revised and sub-bullets describing coding were added
  • Pediatric Regional Nodes [9624]: Note 1 was added describing the information on which this field should be based

• NHL: Burkitt lymphoma; NHL: NOS

  • Schema Definition: C440-C449 were removed from all NHL schemas

• NHL: Mature T-cell and NK-cell lymphomas

  • Schema Definition: C440-C449 were removed from all NHL schemas, 9700-9701, 9718-9719 were removed from NHL Mature T-cell and NK-cell lymphomas

• NHL: Burkitt lymphoma; NHL: Mature T-cell and NK-cell lymphomas; NHL: NOS

  • Pediatric Primary Tuor [9623]: Note 1 related to special terms for involvment was added; Note 2 related on how to code St Jude/Murphy stage was added; all codes were revised; Code 700 was removed
  • Derived Pediatric Stage Group [9606]: the algorithm was revised so that Pediatric Primary Tumor code 300 derived Stage 2 (instead of 3), code 400 and 500 derived Stage 3 (instead of 4 and 2 respectively)

• NHL: Mature B-cell lymphomas

  • Schema Definition: C440-C449 were removed from all NHL schemas, 9971 was removed from NHL Mature B-cell lymphomas
  • Pediatric Primary Tuor [9623]: Note 1 related to special terms for involvment was added; Note 2 related on how to code St Jude/Murphy stage was added; a sub-bullet related to special histologies was added to Note 4; all codes were revised; Code 700 was removed
  • Derived Pediatric Stage Group [9606]: the algorithm was revised so that Pediatric Primary Tumor code 300 derived Stage 2 (instead of 3), code 400 and 500 derived Stage 3 (instead of 4 and 2 respectively)

• Non-Rhabdomyosarcoma: Other specified

  • Schema Definition: C400-C424, C770-C779 were added to the schema for histologies 8587, 8710-8713, 8806, 8831-8833, 8836, 8840-8842, 8850-8858, 8860-8862, 8870, 8880, 8881, 8890-8898, 8921, 8982, 8990, 9040-9044, 9120-9125, 9130-9133, 9135, 9136, 9141, 9142, 9161, 9170-9175, 9231, 9251, 9252, 9373, 9581

• Retinoblastoma

  • Pediatric Primary Tumor [9623]: Note 1 was revised for clarity
  • IRSS Stage For Eye 2 [9627]: Note 2 was removed; new Note 2 was added describing when to code this and special cases; Note 3 was added discussing bilateral retinoblastoma; Note 4 was added describing what to do if only one eye is involved; Code 7 was revised to clarify its use with unilateral retinoblastoma

• Testicular

  • Pediatric Primary Tumor [9623]: Note 3 was added discussing LVI relation to codes 200 and 250

Pediatric 1.0

The field testing version of this API was identified as Toronto Stage and the final version field testing version was Toronto v0.5.
Thanks to all the hard work and thoughtful responses by the Kentucky Cancer Registry, who graciously volunteered to perform the field test for us, and by the countless others who reviewed and contributed to the API, significant changes were made to the system.

The extensive scope of these changes has resulted in a greatly improved Pediatric Data Collection System.

However, since these changes included some paradigm shifts, an audit log of changes between Toronto v0.5 field testing and Pediatric v1.0 Pediatric Data Collection System is not practical.

Some high level changes are presented here.

• System name changed from Toronto to Pediatric. Field names which included the word Toronto were changed to be Pediatric
  • Toronto Version Number [9620] is the sole exception. This field captures the version of the Toronto staging upon which the Pediatric Data Collection System is currently based.
• The age range included in those schemas limited by age changed from 0-19 to the broader 0-39 to be consistent with the NCCR age definitions
• Where appropriate, the capture of Pediatric staging system components moved from distinct SSDIs into the Pediatric Primary Tumor, Pediatric Regional Nodes and Pediatric Mets fields
• Calculations based on EOD 2018 fields were removed from the Pediatric Schema stage group algorithms
  • As an aid to those registries where EOD 2018 is collected, conversion tables for Pediatric Primary Tumor, Pediatric Regional Nodes and Pediatric Mets have been added. These tables, which are outside the Pediatric schemas, ingest the Pediatric Schema ID, EOD 2018 Schema ID, and EOD 2018 fields and, where possible, provide the corresponding value for the Pediatric field. Not all combinations have conversions. These tables are provided to reduce the need for double coding when the value of the EOD 2018 fields captures the same meaning as the Pediatric field.
• Those SSDIs included in the system were reviewed and SSDIs now captured in Pediatric Primary Tumor, Pediatric Regional Nodes and Pediatric Mets were removed, while some additional SSDIs of interest were added

EOD 3.1

Added support for EOD 3.1 #101

EOD v3.1 Review and Conversion:

After EOD v3.1 has been deployed

1. AJCC ID [995]: there were changes to the V9 AJCC ID values to match the AJCC's new numbering scheme. Logic provided for those who CANNOT recalculate across their database.

   • If Date of Diagnosis Year is 2018 or later, for the AJCC ID [995] within each specified Schema ID [3800], the new value is provided:
     • If AJCC ID = 52 and Schema ID = 09520 (Cervix Uteri) and TNM Edition Number = 9 or blank, then set AJCC ID = 9001
     • If AJCC ID = 19 and Schema ID = 09190 (Appendix) and TNM Edition Number = 9 or blank, then set AJCC ID = 9002
     • If AJCC ID = 21 and Schema ID = 09210 (Anus) and TNM Edition Number = 9 or blank, then set AJCC ID = 9003
     • If AJCC ID = 72.1 and Schema ID = 09721 (Brain) and TNM Edition Number = 9 or blank, then set AJCC ID = 9004
     • If AJCC ID = 72.1 and Schema ID = 09722 (CNS Other) and TNM Edition Number = 9 or blank, then set AJCC ID = 9004
     • If AJCC ID = 72.1 and Schema ID = 09723 (Intracranial) and TNM Edition Number = 9 or blank, then set AJCC ID = 9004
     • If AJCC ID = 72.1 and Schema ID = 09724 (Medulloblastoma) and TNM Edition Number = 9 or blank, then set AJCC ID = 9004
     • If AJCC ID = 72.2 and Schema ID = 09724 (Medulloblastoma) and TNM Edition Number = 9 or blank, then set AJCC ID = 9005
   • OR Recalculate to derive the AJCC ID across the database 2018 and later
   • No other changes are necessary
   • (This can always be applied. Calculation tables were updated. No review necessary.)

2. In situ: there were changes to the calculation tables for the Derived EOD 2018 fields in approximately 41 schemas where AJCC does not define Tis. The Derived EOD 2018 N and Derived EOD 2018 M will both be set to 88 for such cases. Logic provided for those who CANNOT recalculate across their database.

   • If Date of Diagnosis Year is 2018 or later, if EOD Primary Tumor = 000 AND Derived EOD 2018 T = 88
     • If Derived EOD 2018 N is not 88, set Derived EOD 2018 N = 88
     • If Derived EOD 2018 M is not 88, set Derived EOD 2018 M = 88
   • OR Recalculate to the Derived EOD 2018 fields across the database for 2018 and later
   • No other changes are necessary
   • (This can always be applied. Calculation tables were updated. No review necessary.)

3. Grade: there were changes to the calculation tables for the Derived EOD 2018 Stage Group in 8 schemas where Grade is considered for stage group determination. The calculation no longer prioritizes by timing, but now uses the highest grade captured between Grade Clinical [3843] and Grade Pathological [3844]. Also, for Retroperitoneum and Soft Tissue Trunk and Extremities, the Grade value of ‘H’ was added to the Grade tables in v3.0 but had not been added to the Stage Group calculation tables – this has been corrected. If Derived EOD 2018 Stage Group is collected, it will need to be recalculated.

   • If Date of Diagnosis Year is 2018 or later, if Schema ID [3800] in 00190 (Appendix 8th), 09190 (Appendix V9), 00381 (Bone Appendicular Skeleton), 00480 (Breast), 00430 (GIST), 00580 (Prostate), 00440 (Retroperitoneum), 00410 (Soft Tissue Trunk and Extremities)
     • Recalculate to the Derived EOD 2018 fields across the database for 2018 and later
   • No other changes are necessary
   • (This can always be applied. Calculation tables were updated. No review necessary.)

4. Grade: Derived Summary Grade [1975] has been defined. This field will be calculated at the central registries for all cases diagnosed 2018 and later. The more severe value from Grade Clinical [3843] and Grade Pathological [3844] will be used. Breast is a special case because behavior affects the priority. If this field is required for your registry:

   • If Date of Diagnosis Year is 2018 or later
     • If Schema ID [3800] = 00480 (Breast), Set Derived Summary Grade to the highest value found in Grade Clinical and Grade Pathology where the priority order from BEST to WORST is (Table can be found at: https://staging.seer.cancer.gov/eod/table/3.1/combined_grade_breast_8723/)
       • For Behavior /2: H, M, L, 3, 2, 1, D, C, B, A, 9, blank
       • For Behavior /3: 3, 2, 1, H, M, L, D, C, B, A, 9, blank
     • Else (all other schema), Set Derived Summary Grade to the highest value found in Grade Clinical and Grade Pathology where the priority order from BEST to WORST is (Table can be found at: https://staging.seer.cancer.gov/eod/table/3.1/combined_grade_56638/)
       • S, 5, 4, 3, 2, 1, E, D, C, B, A, H, M, L, 9, blank
   • No other changes are necessary
   • (This can always be applied. No review necessary.)

5. SEER Site Specific Factor 1 [3700]: the field is changing from a 1 digit fields to a 2 digit field. There is a conversion between the old values and the new.

   • For the Schema ID [3800], the conversion between the old and new values of SEER Site Specific Factor 1 is provided:
   • If Date of Diagnosis Year is prior to 2018, set SEER Site Specific Factor 1 to blank.
   • Else If Date of Diagnosis Year is 2018 or later

     • If Schema ID [3800] = 00071 (Lip), 00072 (Tongue Anterior), 00073 (Gum), 00074 (Floor of Mouth), 00075 (Palate Hard), 00076 (Buccal Mucosa), 00077 (Mouth Other), 00112 (Hypopharynx), 00100 (Oropharynx HPV-Mediated (p16+)), 00111 (Oropharynx (p16-))

       • If SEER Site Specific Factor 1 = 0 then set SEER Site Specific Factor 1 = 20
       • Else If SEER Site Specific Factor 1 = 1 then set SEER Site Specific Factor 1 = 21
       • Else If SEER Site Specific Factor 1 = 2 then set SEER Site Specific Factor 1 = 30
       • Else If SEER Site Specific Factor 1 = 3 then set SEER Site Specific Factor 1 = 31
       • Else If SEER Site Specific Factor 1 = 4 then set SEER Site Specific Factor 1 = 40
       • Else If SEER Site Specific Factor 1 = 5 then set SEER Site Specific Factor 1 = 41
       • Else If SEER Site Specific Factor 1 = 6 then set SEER Site Specific Factor 1 = 50
       • Else If SEER Site Specific Factor 1 = 7 then set SEER Site Specific Factor 1 = 51

     • If Schema ID [3800] = 00071 (Lip), 00072 (Tongue Anterior), 00073 (Gum), 00074 (Floor of Mouth), 00075 (Palate Hard), 00076 (Buccal Mucosa), 00077 (Mouth Other), 00112 (Hypopharynx)

       • If SEER Site Specific Factor 1 = 8 then set SEER Site Specific Factor 1 = 97
       • Else If SEER Site Specific Factor 1 = 9 then set SEER Site Specific Factor 1 = 99

     • Else If Schema ID [3800] = 00100 (Oropharynx HPV-Mediated (p16+)) Schema Discriminator 2 [3927] must be 2 for this schema

       • If SEER Site Specific Factor 1 = 8 then set SEER Site Specific Factor 1 = 11
       • Else If SEER Site Specific Factor 1 = 9 then set SEER Site Specific Factor 1 = 11

     • Else If Schema ID [3800] = 00111 (Oropharynx (p16-)) Schema Discriminator 2 [3927] must be 1 or 9 for this schema

       • If SEER Site Specific Factor 1 = 8 and Schema Discriminator 2 = 1 then set SEER Site Specific Factor 1 = 10
       • Else If SEER Site Specific Factor 1 = 8 and Schema Discriminator 2 = 9 then set SEER Site Specific Factor 1 = 97
       • Else If SEER Site Specific Factor 1 = 9 and Schema Discriminator 2 = 1 then set SEER Site Specific Factor 1 = 10
       • Else If SEER Site Specific Factor 1 = 9 and Schema Discriminator 2 = 9 then set SEER Site Specific Factor 1 = 99
   • No other changes are necessary
   • (This can always be applied. No review necessary.)

EOD v3.1 changes:

EOD and SS2018 - includes changes to schema definitions, EOD fields and SS2018

• General Changes

  • LVI: LVI was removed from all schemas. The values shown had been limited to those applicable to the schema but a single lookup (available in NAACCR) can be used.

  • Version 9 Updated Diseases: AJCC released the 9th revision of the NET (excluding Adrenal Gland) and Vulva diseases which will be effective for cases diagnosed 1/1/2024 or later. There are now 2 schemas for each.

    • NET Ampulla of Vater [8th: 2018-2023], Schema ID [#3800] = 00302
    • NET Ampulla of Vater [V9: 2024+], Schema ID = 09302
    • NET Appendix [8th: 2018-2023], Schema ID [#3800] = 00320
    • NET Appendix [V9: 2024+], Schema ID = 09320
    • NET Colon and Rectum [8th: 2018-2023], Schema ID [#3800] = 00330
    • NET Colon and Rectum [V9: 2024+], Schema ID = 09330
    • NET Duodenum [8th: 2018-2023], Schema ID [#3800] = 00301
    • NET Duodenum [V9: 2024+], Schema ID = 09301
    • NET Jejunum and Ileum [8th: 2018-2023], Schema ID [#3800] = 00310
    • NET Jejunum and Ileum [V9: 2024+], Schema ID = 09310
    • NET Pancreas [8th: 2018-2023], Schema ID [#3800] = 00340
    • NET Pancreas [V9: 2024+], Schema ID = 09340
    • NET Stomach [8th: 2018-2023], Schema ID [#3800] = 00290
    • NET Stomach [V9: 2024+], Schema ID = 09290
    • Vulva [8th: 2018-2023], Schema ID [#3800] = 00500
    • Vulva [V9: 2024+], Schema ID = 09500

  • Version 9 Updates IDs: AJCC ID [#995] has been revised by the AJCC. This affects the AJCC IDs for Cervix Uteri V9, Appendix V9, Anus V9, Brain and Spinal Cord Other V9, and Brain and Spinal Cord Medulloblastoma V9. Please see the AJCC DLL's change log for more information. (See 'EOD v3.1 Review and Conversion')

  • In Situ Calculation: For those schemas where AJCC does not define Tis but EOD Primary Tumor includes 000 for In situ, the Derived EOD 2018 T was being set to 88, but the Derived EOD 2018 N and Derived EOD 2018 M were being set based on the normal logic for the coded value. New calculation logic has been added to ensure that for these schema, if EOD Primary Tumor is set to 000, all of Derived EOD 2018 T, Derived EOD 2018 N, Derived EOD 2018 M an...

Toronto Pediatric 0.5

This release of v0.5 also includes changes from v0.4 and v0.3 which were never officially released. See #99 for details.

v0.5 changes:

For most registries this will be the initial version and neither the changes below nor the changes for v0.2 - v0.4 are relevant

Conversions - for Kentucky only

• If Toronto Schema ID = 1b (AML) or 1c (CML)
  • Recalculate - Case will go to Adult schema, these schemas were dropped. They did not have extra fields.
• If Toronto Schema ID = 1a1 (ALL)
  • If White Blood Cell Count = XXXXX.3, change to XXXXX.4
  • If White Blood Cell Count = XXXXX.2, change to XXXXX.3
• If Toronto Schema ID = 3b (Astro)
  • Blank out M Category
• If Toronto Schema ID = 3a (Epend), 3c1, 3c2, 3c3, 3c4, 3e3 (Medullo)
  • If M Category = 1-4, add trailing 5. if M Category = 0, change to 00; if M Category = 8, change to 88; if M Category = 9, change to 99
• If Toronto Schema ID = 6a1, 6a2, 6a3, 6a4, 6c (Renal)
  • If Wilms Staging System = 50, set to 99
  • Set Chromosome 19q: Loss of Heterozygosity (LOH) [3802] to blank - 19q has been dropped; 16q has been added, but they are NOT the same thing.
• If Toronto Schema ID = 9a
  • If High Risk Cytogenetics [3857] = 0,1,7,8,9, set FOXO1 Gene Rearrangements [9609] = High Risk Cytogenetics
  • If High Risk Cytogenetics = 2, set FOXO1 Gene Rearrangements = 4; Set High Risk Cytogenetics [3857] to blank
  • SSDI valid in other schemas, just not here
• Remove Derived Risk Level [3964] DNA Ploidy [3962], Chromosome 11q Status [3983]
  • These SSDIs were also dropped
• Rename Shimada Classification to be International Neuroblastoma Pathology Classification (INPC):
  • (Add International Neuroblastoma Pathology Classification (INPC) [9610]
  • Copy value from Shimada Classification [3974]
  • Remove Shimada Classification [3974])

General

• SSDI Temporary NAACCR Item Numbers: All temporary item numbers were moved to 9600-9622 range
• SSDI effective range: For Note 1 in all SSDIs, the effective diagnosis years are 2023+, which is also reflected in the blank value of the validation tables. The SSDI meta data does not have this limitation to support registries who collected information for earlier cases, but it is neither expected nor required.

Acute Lymphoblastic Leukemia

• CNS Involvement [9602]: Note 2 and all codes changed so that a physician's documentation of CNS Involvement should be captured in text, but not used to code the data item; Codes 2 and 3 adjusted for bullet spacing and to include equal (<= or >=) in the breakpoint descriptions
• White Blood Cell Count [9621]: Notes 3 and 4 were changed to be sub-bullets of Note 2 and examples were added; Code XXXXX.2 was modified to mean LOW; XXXXX.3 was modified to be NORMAL and XXXXX.4 was added to be ELEVATED/HIGH

Acute Myeloid Leukemia, Chronic Myeloid Leukemia

• These schema were removed. The Site/Histology combinations were moved into the Adult/Non-Pediatric schema.

Adult/Other Non-Pediatric

• The Site/Histology combinations for AML and CML were added

Astrocytoma

• M Category: this SSDI was removed; EOD Mets [776] will be used to determine stage

Ependymoma, Medulloblastoma, Medulloblastoma: Atypical teratoid/rhabdoid, Medulloblastoma: Medulloepithelioma, Medulloblastoma: Pineobloastoma, Medulloblastoma: pNET

• M Category [9613]: Note 2 and all codes changed so that a physician's documentation of M Category should be captured in text, but not used to code the data item; Note 3 added describing how to treat /0 and /1; Codes changed to 00, 15, 25, 35, 45, 88 and 99; Code 70 added for Distant Mets NOS; Code 99 had 'M category not assessed' added.

Malignant Bone Tumors: Ewing, Renal Tumors: Ewing Sarcoma of Kidney

• EWSR1-FLI1 Fusion [9608]: renamed from EWS-FLI1 fusion; Codes 2 through 5 added to capture -ERG, Other, Unknown type of rearrangements and non-EWSR1 variant translocation; Code 9 had 'cannot be determined by pathologist' added

Neuroblastoma

• Derived Risk Level: this SSDI and its derivation calculation was removed
• DNA Ploidy, Chromosome 11q Status: these SSDIs were removed
• Age at Diagnosis [230], Grade Clinical [3843], Grade Pathological [3844]l, Grade Post Therapy Clin (yc) [1068], Grade Post Therapy Path (yp) [3845], Month of Birth, Month of Diagnosis: these fields are no longer needed for calculations in this schema and were removed from the data item list
• International Neuroblastoma Risk Group Staging System [9611]: Note 2 revised to be a clearer statement that this data should be from clinical work; Note 3 added and codes revised to indicate that registrar must assign INRGSS, physician statement should be captured in text; Note 4 revised for structure; Note 6 added and codes revised addressing on Regional lymph node involvement; Code 4 modified to add "MIBG scintigraphy must be negative in bone and bone marrow" as a sub-bullet under Bone Marrow.
• n-MYC Amplification [9614]: Codes 0 and 1 simplified; Code 2 added for 'Gain'; Code 9 modified to add 'cannot be determined by pathologist' and not applicable
• International Neuroblastoma Pathology Classification (INPC) [9610]: SSDI renamed from Shimada Classification, which is now the alternate name; Notes reworded, Note 4 was removed; ode 9 modified to add 'cannot be determined by pathologist'

NHL: Burkitt Lymphoma, NHL: Mature B-cell lymphoma, NHL: Mature T-cell and NK-cell lymphoma, NHL: NOS

• St Jude/Murphy Staging System [9615]: Note 2 revised to indicate that registrar must assign St Jude/Murphy Staging System, physician statement should be captured in text; Note 3 removed; Code 2 and 4 minor text updates; Code 4 adjusted to include equal (>= 5%); Code 7 added for Not applicable histologies

NHL: Mature B-cell lymphoma

• Schema Selection: 9679, 9761-9762, 9765, 9769, 9970-9971 with C000-C809, Behavior = 3, ages 0-19 moved from Adult/Other Non-Pediatric to NHL: Mature B-cell lymphoma

NHL: Mature T-cell and NK-cell lymphoma

• Schema Selection: 9700-9701, 9718-9719 with C000-C809, Behavior = 3, ages 0-19 moved from Adult/Other Non-Pediatric to NHL: Mature T-cell and NK-cell lymphoma

Non-Rhabdomyosarcoma: Fibrosarcoma, Non-Rhabdomyosarcoma: Other specified, Non-Rhabdomyosarcoma: Unspecified

• Toronto Grade [9616]: Derivation changed to be highest grade of Grade Clinical [3843] and Grade Pathological [3844]
• Grade Post Therapy Clin (yc) [1068], Grade Post Therapy Path (yp) [3845]: these fields are no longer needed for calculations in this schema and were removed from the data item list

Ovarian

• Title: removed 'Copy' from full name

Renal Tumors: Ewing Sarcoma of Kidney, Renal Tumors: Kidney Sarcomas, Renal Tumors: Nephroblastoma, Renal Tumors: Rhabdoid Renal Tumor, Renal Tumors: Unspecified Malignant Renal Tumors

• Wilms Tumor Staging System [9622]: default set to blank; Note 2 added and codes revised to indicate that registrar must assign Wilms Tumor Staging System, physician statement should be captured in text; Notes 2 and 3 minor revisions; Note 4 added for bilateral disease; Code 20 had 'No nodal or hematogenous metastases AND Negative margins' added; Code 50 Stage V was removed
  Chromosome 19q: Loss of Heterozygosity (LOH): this SSDIs was removed
• Chromosome 16q [9600]: Loss of Heterozygosity (LOH): this SSDIs was added (very similar to 19q, but is long arm rather than short, and chromosome 16 rather than 19)

Retinoblastoma

• International Retinoblastoma Staging System [9612]: Note 2 and codes revised to indicate that registrar must assign International Retinoblastoma Staging System, physician statement should be captured in text; Note 3 related to having more than one stage was removed; new Note 3 about bilateral disease was added;

Rhabdomyosarcoma

• High Risk Cytogenetics [3857]: this SSDIs was removed
• FOXO1 Gene Rearrangements [9609]: this SSDI was added

v0.4 changes:

• Acute Lymphoblastic Leukemia
  • White Blood Cell Count: field and all values were lengthened to 7 (XXXXX.1)

v0.3 changes

General Changes

• SSDI validation tables: if the actual text string "< BLANK >" was in the input value list, it was removed so the cell is actually blank

Toronto Pediatric 0.4

• Updated Toronto Pediatric algorithm (#96)